Theralase Technologies Inc (TLTFF)

[123414]

$TLTFF - receives a target raise from Research Capital

Published on April 5, 2022

New interim clinical data has Research Capital Corporation analyst Andr Uddin feeling more bullish about Canadian drug developer Theralase Technologies (Theralase Technologies Stock Quote, Charts, News, Analysts, Financials TSXV:TLT). Uddin maintained a “Speculative Buy” rating while raising his target price from $0.70/share to $1.20/share for a projected return of 161 per cent in an update to clients on Tuesday.

Theralase Technologies receives a target raise from Research Capital (cantechletter.com/)